Fibrocell (NASDAQ:FCSC) announced its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06, MarketWatch Earnings reports.
Shares of Fibrocell opened at $0.62 on Friday, according to Marketbeat Ratings. The firm has a market cap of $17.58 million, a price-to-earnings ratio of -0.38 and a beta of 0.45. Fibrocell has a 12-month low of $0.60 and a 12-month high of $0.62.
Several research analysts recently issued reports on the company. HC Wainwright set a $6.00 price objective on Fibrocell and gave the stock a “buy” rating in a research note on Thursday. ValuEngine raised Fibrocell from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research cut Fibrocell from a “buy” rating to a “hold” rating in a research note on Tuesday, February 6th. Finally, Griffin Securities reaffirmed a “buy” rating on shares of Fibrocell in a research report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Fibrocell has an average rating of “Hold” and a consensus price target of $4.58.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Sabby Management LLC bought a new stake in Fibrocell during the 4th quarter valued at $733,000. Armistice Capital LLC bought a new stake in Fibrocell during the 4th quarter valued at $393,000. Anson Funds Management LP bought a new stake in Fibrocell during the 4th quarter valued at $287,000. FNY Partners Fund LP bought a new stake in Fibrocell during the 4th quarter valued at $129,000. Finally, Third Security LLC boosted its position in Fibrocell by 49.2% during the 4th quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock valued at $5,292,000 after acquiring an additional 2,727,273 shares in the last quarter. 44.07% of the stock is currently owned by institutional investors and hedge funds.
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Receive News & Ratings for Fibrocell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell and related companies with MarketBeat.com's FREE daily email newsletter.